Influenza Vaccine Market Outlook, Trends Forecast 2024–2030
The report “Influenza Vaccine Market by Vaccine Type (Quadrivalent and Trivalent), By Technology (Egg-based, and Cell Culture), By Age Group (Pediatric, and Adult), By Route of Administration (Injection, and Nasal Spray) — Global Forecasts to 2030”, is projected to reach USD 7.32 billion in 2023, registering at a Compound Annual Growth Rate (CAGR) of 6.5% during the forecast period 2024–2030. The growth of the influenza vaccine market is majorly driven by the rising government initiatives for spreading awareness.
Influenza can be prevented most effectively with vaccination. It lessens the intensity of symptoms if an infection does emerge and aids in preventing people from getting the illness. For all individuals six months of age and above, the flu vaccination is advised. Effective influenza vaccinations are in high demand, and as a result, the market for these vaccines is expanding significantly. The market is expanding due to the rising incidence of influenza and the pressing need for prevention.
Request sample report at https://www.precisionbusinessinsights.com/request-sample/?product_id=16918
Scope of The Report:
- The Influenza Vaccine market research report includes historical data, trending features, and market growth estimates for the future.
- The Qualitative and quantitative analysis of the market along with CAGR calculation for the forecast period.
- The market report helps to provide the best results for business enhancement and business growth.
- The report gives a comprehensive overview of both primary and secondary data.
- The market key players covered here to help them strengthen their place in the market.
Regional Overview:
The report also examines the current concerns and their Future Effects on the Influenza Vaccine Market by the region. The report covers all regions and countries, North America was the largest and Asia was the fastest-growing region in the Influenza Vaccine Market. The market has been segmented into numerous primary regions and a detailed evaluation of primary countries.
- North America (U.S., Canada)
- Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
- Asia-Pacific (China, India, Japan, Australia, Southeast Asia, Rest of Asia Pacific)
- Latin America (Mexico, Brazil, Argentina, Columbia, Rest of Latin America)
- Middle East & Africa (GCC, Egypt, Nigeria, South Africa, Rest of Middle East and Africa)
The prominent key players operating in the global Influenza Vaccine market are GSK plc, AstraZeneca, SINOVAC, Vaxess Technologies Inc, Pfizer Inc, CSL Limited, EMERGENT, Merck & Co., Inc., Viatris Inc., OSIVAX, EMERGEX VACCINES